U.S. Markets close in 1 hr 57 mins

Incyte Corporation (INCY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
134.78-3.49 (-2.52%)
As of 2:03PM EDT. Market open.
People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close138.27
Open134.13
Bid134.93 x 200
Ask135.07 x 100
Day's Range132.88 - 136.95
52 Week Range75.52 - 153.15
Volume1,272,545
Avg. Volume1,707,807
Market Cap27.6B
Beta1.80
PE Ratio (TTM)-239.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Eli Lilly Tumbles On Arthritis Drug Delay, Light Q2 Sales
    Investor's Business Daily37 minutes ago

    Eli Lilly Tumbles On Arthritis Drug Delay, Light Q2 Sales

    A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.

  • Barrons.com2 hours ago

    Eli Lilly: What the Heck Just Happened?

    Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY). Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion. Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed.

  • MarketWatch7 hours ago

    Eli Lilly beats profit and sales expectations; NDA for RA treatment to be delayed

    Eli Lilly & Co. reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, ...